Last week, the U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants with cystic fibrosis ages 1 month to 4 months who have certain mutations. Although this approval affects a very small number of infants, it is another important step in making sure that everyone with CF has a treatment for the underlying cause of their disease. 

Read the announcement »

During the pandemic, the continuous coverage provision helped stave off lapses in health care coverage for people with cystic fibrosis who utilize Medicaid. With states’ redetermination processes resuming, the Foundation is advocating to limit coverage loss and facilitate a smooth transition for all those impacted. 

Read about the impact »

Mark your calendars for Wednesday, June 7 at 7 p.m. ET for the first-ever national passion fundraising workshop. During this virtual workshop, attendees will receive a passion fundraising toolkit, hear from other Foundation volunteers, participate in breakout groups, and network with others in the CF community. 

Register now »

People with cystic fibrosis are living longer than ever before. The median predicted survival for someone with CF is now 56, meaning half of the people born between 2018 and 2022 are predicted to live to 56 years or more. On the CF Community Blog, Art Brace, a 57-year-old with CF, shares how his health needs are becoming more complex as he ages.   

Read Art's story »